CUSIP: 64049K104
Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
25,131,800
-
Share change
-
+2,383,463
-
Total reported value
-
$417,161,785
-
Put/Call ratio
-
123%
-
Price per share
-
$16.60
-
Number of holders
-
72
-
Value change
-
+$48,829,284
-
Number of buys
-
52
-
Number of sells
-
25
Quarterly Holders Quick Answers
What is CUSIP 64049K104?
CUSIP 64049K104 identifies NLTX - NEOLEUKIN THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2020
-
Previous quarter:
Q1 2020
Recent filing periods for CUSIP 64049K104:
Institutional Holders of NEOLEUKIN THERAPEUTICS INC - COM (NLTX) as of Q2 2020
As of 30 Jun 2020,
NEOLEUKIN THERAPEUTICS INC - COM (NLTX) was held by
72 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,131,800 shares.
The largest 10 holders included
Redmile Group, LLC, EcoR1 Capital, LLC, BAKER BROS. ADVISORS LP, BlackRock Inc., PICTET ASSET MANAGEMENT LTD, Opaleye Management Inc., RENAISSANCE TECHNOLOGIES LLC, BOXER CAPITAL, LLC, VANGUARD GROUP INC, and Fairmount Funds Management LLC.
This page lists
72
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.